Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene
- 25 November 2015
- journal article
- research article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 58 (1) , 30-36
Abstract
Recombinant AAV (rAAV) vectors are a suitable vector for gene therapy studies because of desired characteristics such as low immunogenicity, transfection of non-dividing and dividing cells, and long-term expression of the transgene. In this study, the large-scale production of single stranded (ss) and self-complementary (sc) AAV9 carrying the human survival motor neuron (SMN) gene (AAV9-SMN) suitable for in vivo gene therapy studies of SMA was described. SMN cDNA has been cloned into pAAV-CB6-PI and pAAVsc-CB6-PI with and without its specific UTRs, respectively. Both plasmids bear CMV enhancer/beta-actin (CB) promoter, CMV IE enhancer, and polyadenylation signal sequences. 2.5 μg of constructed pAAV-CB6-PI-SMN and pAAVsc-CB6-PI-SMN cause to, respectively, 4.853- and 2.321-fold increases in SMN protein levels in transfected cells compared to untransfected cells. Ss and scAAV9-SMN vectors were also produced from these plasmids by transient transfection of HEK293 cells using CaCl2 solution. The silver staining and electron microscopy analysis demonstrated good quality of both isolated vectors, ssAAV9-SMN and scAAV9-SMN, with the titers of 2.00E+13 and 1.00E+13 GC/ml. The results of this study show that, the plasmid containing UTR elements causes to twice more SMN gene expression in transfected cells. The quality control results show that both produced ss and scAAV9-SMN are suitable for in vivo studies.Keywords
Funding Information
- National Institutes of Health (R01NS076991-01, 1R21DA031952-01A, 2P01HL059407, 1P01AI100263-01)
- National High Technology Research and Development Program (2012AA020810)
This publication has 15 references indexed in Scilit:
- Intramuscular scAAV9-SMN Injection Mediates Widespread Gene Delivery to the Spinal Cord and Decreases Disease Severity in SMA MiceMolecular Therapy, 2013
- Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications2012
- Spinal muscular atrophyOrphanet Journal of Rare Diseases, 2011
- Exploiting Natural Diversity of AAV for the Design of Vectors with Novel Properties2011
- Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease)Orphanet Journal of Rare Diseases, 2011
- Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA miceHuman Molecular Genetics, 2010
- Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at ScaleHuman Gene Therapy, 2010
- RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMNNature Biotechnology, 2010
- Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular AtrophyThe American Journal of Human Genetics, 2002
- Inclusion of the Hepatic Locus Control Region, an Intron, and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in VitroMolecular Therapy, 2000